SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Genstar GNT(formerly UroGen)-- an interesting speculation
An SI Board Since June 1998
Posts SubjectMarks Bans Symbol
100 3 0 GNT
Emcee:  Paul Lee Type:  Unmoderated
Introduction Market Data Compact
UroGen is a biotechnology company currently developing products for the diagnosis and treatment of prostate cancer. If the acquisition of the gene transfer system is successful, the Company's charter will expand to include treatments for other forms of cancer and genetic disorders.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
100GenStar Therapeutics and Vascular Genetics Announce Completion of Merger to FormPaul Lee-2/6/2003
99So are they or aren't they going forward with hemophilia and HIV programs? tuck-11/14/2002
98from CEOcast newsletter Sunday, September 15 2002 VOLUME XXXXVIII Genstar ThPaul Lee-9/16/2002
97biz.yahoo.com Autus Genetics Corp* to be Created by the Merger of Vascular GenePaul Lee-9/13/2002
96GenStar Therapeutics Reports Second Quarter 2002 Financial Results BUSINESS WIREPaul Lee-8/14/2002
95GenStar Therapeutics Appoints Creighton W. Lawhead as Senior Vice President and Paul Lee-6/27/2002
94SPECIAL SITUATIONS Genstar Therapeutics (AMEX: GNT) $0.48 The recent decline in Paul Lee-6/23/2002
93update of the Company's hemophilia A clinical trial program today at the AmePaul Lee-6/6/2002
92First Quarter Ended March 31, 2002 SAN DIEGO--(BW HealthWire)--May 14, 2002--GenPaul Lee-5/14/2002
91GenStar Therapeutics Announces Research Agreement with Centocor BUSINESS WIRE - Paul Lee-5/8/2002
90GenStar Therapeutics Reports Financial Results and Operating Highlights for the Paul Lee-4/4/2002
89GenStar Therapeutics Presents at NYSSA Biotechnology Conference Update Provided Paul Lee-3/27/2002
88GenStar's Cancer Product Suppresses the Growth of Prostate Tumors and EnhancPaul Lee-12/17/2001
87GenStar Reports Successful Repeated Administration of MAX-AD FACTOR VIII in Pre-Paul Lee-12/10/2001
86SAN DIEGO, Calif.--(BW HealthWire)--Nov. 13, 2001--GenStar Therapeutics (AMEX: GPaul Lee-11/13/2001
85GenStar Therapeutics Announces NIH Innovation Grants for Hemophilia and HIV/AIDSPaul Lee-11/7/2001
84trial restarts GenStar Therapeutics Announces Regulatory Progress of the CompaPaul Lee-9/25/2001
83SAN DIEGO--(BW HealthWire)--Aug. 14, 2001--GenStar Therapeutics (AMEX: GNT - newPaul Lee-8/14/2001
82<i>transient liver chemistries and hematologic abnormalities were observedSnowShredder-7/12/2001
81GenStar Thera: Study Shows MAX-AD Raises Clotting Factor Dow Jones Newswires Paul Lee-7/12/2001
80looks good to me GenStar Reports Clinical Results of the First Patient to ReceiPaul Lee-7/11/2001
79Susan E. Atkins & Associates Adds Four San Diego Companies to Growing RosterPaul Lee-6/21/2001
78About bloody time. Human trials were supposed to begin last fall, and we never tuck-6/18/2001
77GenStar Therapeutics Initiates Phase I Gene Therapy Clinical Trial for HemophiliPaul Lee-6/18/2001
76You are right. TKTX is Transkaryotic. The WSJ article has brought this area to tElliot Lepler-6/11/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News